Table 2.
Demographics for DSP UC Patients
| Case | Baseline endoscopy | Description | Follow-up endoscopy and histology | Clinical outcome |
|---|---|---|---|---|
| UC patients treated with hyperbaric oxygen during hospitalization for acute severe flare | ||||
| 1 | MES 3 with ulcers | Male, biologic and immunomodulator naive before hospitalization, clinical response to HBOT by days 3 and 5 | MES 1, no friability; histology with persistence of neutrophils | Relapse requiring infliximab in 3 months |
| 2 | MES 3 with ulcers | Female, 1 prior anti-TNF agent (adalimumab) which patient was failing at time of hospitalization, clinical response to HBOT by days 3 and 5 | MES 0, normal vascular pattern; histology with persistence of neutrophils | Able to maintain response for 3 months with continued adalimumab, later relapsed requiring vedolizumab |
| 3 | MES 3 with ulcers | Male, prior failure of 2 anti-TNF agents (infliximab, adalimumab), vedolizumab, and failing 10 mg PO BID tofacitinib at time of hospitalization, clinical response to HBOT by days 3 and 5 | MES 1, no friability; histology with persistence of neutrophils | Able to remain colectomy free on 5 mg PO BID tofacitinib |
| UC patients treated with standard of care in outpatient setting for acute severe flare | ||||
| 4 | MES 3 with ulcers | Female, biologic and immunomodulator naive, started on vedolizumab after baseline endoscopy | MES 1, no friability; histology with persistence of neutrophils | Good clinical response with later requirement for Q4 week vedolizumab |
| 5 | MES 3 with ulcers | Female, prior failure of 2 anti-TNF agents (infliximab, adalimumab), and failing vedolizumab at time of baseline endoscopy, started on golimumab after baseline endoscopy | MES 1, no friability; histology with persistence of neutrophils | Good clinical response with maintenance on golimumab |
| 6 | MES 3 with ulcers | Female, 1 prior anti-TNF agent (infliximab) which patient was failing at time of baseline endoscopy, started vedolizumab after baseline endoscopy | MES 0, normal vascular pattern; histology with persistence of neutrophils | Good clinical response with maintenance on vedolizumab |
Anti-TNF, anti–tumor necrosis factor antagonist; BID, twice daily; MES, Mayo endoscopic subscore; PO, oral; Q4, every 4.